Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening

Human Psychopharmacology

Volumn 16, Issue 2, 2001, Pages 159-167

  Hindmarch, Ian ^a   Patat, Alain ^b   Stanley, Neil ^a   Paty, Isabelle ^b   Rigney, Una ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b Searle European Clinical R and D   (France)

Author keywords

Choice reaction time; Critical flicker fusion; Digit symbol substitution test; Zaleplon; Zolpidem

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; PLACEBO; ZALEPLON; ZOLPIDEM;

ADULT; AROUSAL; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL FLICKER FUSION; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG USE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEMORY; METHODOLOGY; NIGHT; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SCORING SYSTEM; TASK PERFORMANCE; WORD RECOGNITION;

EID: 0035083521     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.282     Document Type: Article

References (36)

1. Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunizatrepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics
2. A review of the preclinical development of zaleplon, a novel nonbenzodiazepine hypnotic for the treatment of insomnia
3. Comparisons of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects
4. Residual effects of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades
5. Benzodiazepines, memory and mood: A review
6. A receptors different from zolpidem, zopiclone and benzodiazepines
7. A comparison of the residual effects of zaleplon and zolpidem following administration five to two hours before awakening
8. Overall peak psychomotor and memory effects of zaleplon: Consistency of results throughout all 19 pharmacology studies
9. Zaleplon: A review of its use in the treatment of insomnia
10. The effects of acute and repeated dose of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers
11. Does zolpidem have unique clinical properties A pharmacodynamic comparison with triazolam and placebo
12. Comparative kinetics and dynamics of zaleplon, zolpidem and placebo
13. Psychomotor and psychoactive drugs
14. Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia
15. Impact of insomnia on health-related quality of life
16. Sedative-hypnotics and human performance
17. Benzodiazepines and vigilance performance: A review
18. Memory, psychomotor and cognitive functions after treatment with zolpidem
19. Zolpidem: A review of its pharmacodynamic and pharmacokinetics properties and therapeutic potential
20. Epidemiology of sleep disorders
21. Pharmacological treatment of insomnia
22. Sleep disturbance. A component of health status
23. The effects of practice on choice reaction time and critical flicker fusion
24. Clinical pharmacology of psychoxropic drugs
25. Study effects of clobazam and lorazepam on memory and cognitive functions in healthy subjects
26. EEG profile of intravenous zolpidem in healthy volunteers
27. Effects of zolpidem on saccadic eye movements and psychomotor performance: A double-blind, placebo-controlled study in healthy volunteers
28. Recent developments in the behavioral pharmacology of benzodiazepine (T) receptors: Evidence for the functional significance of receptor subtypes
29. Comparison of the pharmacological profiles of the hypnotic drugs zaleplon and zolpidem
30. Sleep in a noisy environment: Hypnotic and residual effect of zaleplon
31. Comparison of the effects of zaleplon, zolpidem and triazolam on memory, learning and psychomotor performance
32. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance
33. Residual effects of zaleplon and zopiclone on actual driving
34. The impact on car-driving ability of zaleplon or zolpidem after a middle of the night administration
35. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia
36. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia